Ranked #1,603 of 8,699 institutional investors
Casdin Capital, LLC
New York, NY
$1.83B
US stock portfolio at live prices · today −$709K (−0.04%)
Live prices, last trade 9:55 AM ET
- Value at quarter end (Q3 2026)
- $2.30B
- Change from Q2 2026
- +$297.9M (+14.91%)
- Positions
- 46 · 7 new, 2 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$178M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesRVMD 23.0%RLAY 13.9%WGS 9.81%ILMN 5.71%GRAL 3.77%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. | 2,577,333 | $422M | 23.0% | Unchanged |
| RLAY Relay Therapeutics, Inc. | 16,035,240 | $254M | 13.9% | Unchanged |
| WGS GeneDx Holdings Corp. | 3,707,164 | $180M | 9.81% | Unchanged |
| ILMN Illumina, Inc. | 530,000 | $105M | 5.71% | Unchanged |
| GRAL GRAIL, Inc. | 680,000 | $69.0M | 3.77% | Added +42% |
| TXG 10x Genomics, Inc. | 1,050,000 | $56.7M | 3.09% | Unchanged |
| LAB Standard BioTools Inc. | 88,783,856 | $53.6M | 2.92% | Unchanged |
| SRRK Scholar Rock Holding Corporation | 850,000 | $43.6M | 2.38% | Added +28% |
| NGNE Neurogene Inc. | 1,585,361 | $35.8M | 1.95% | Added +3% |
| PSNL Personalis, Inc. | 2,300,000 | $33.3M | 1.82% | Reduced −10% |
| BEAM Beam Therapeutics Inc. | 1,500,000 | $32.4M | 1.77% | Added +11% |
| MAZE Maze Therapeutics, Inc. | 843,857 | $27.1M | 1.48% | Unchanged |
| GH Guardant Health, Inc. | 185,000 | $26.4M | 1.44% | Unchanged |
| SRPT Sarepta Therapeutics, Inc. | 1,820,000 | $25.9M | 1.41% | Added +287% |
| TEM Tempus AI, Inc. | 423,597 | $24.2M | 1.32% | New |
| DNLI Denali Therapeutics Inc. | 1,250,000 | $23.2M | 1.26% | Reduced −39% |
| SEPN Septerna, Inc. | 553,268 | $21.6M | 1.18% | Unchanged |
| PBLS Parabilis Medicines, Inc. | 645,690 | $18.2M | 0.99% | Unchanged |
| ALNY Alnylam Pharmaceuticals, Inc. | 120,000 | $17.9M | 0.98% | Added +60% |
| GPCR Structure Therapeutics Inc. | 1,030,000 | $17.4M | 0.95% | Reduced −12% |
| MRNA Moderna, Inc. | 75,000 | $15.6M | 0.85% | Unchanged |
| TSHA Taysha Gene Therapies, Inc. | 3,900,000 | $14.6M | 0.80% | Added +20% |
| DGX Quest Diagnostics Incorporated | 50,000 | $13.1M | 0.71% | Unchanged |
| HIMS Hims & Hers Health, Inc. | 800,000 | $12.6M | 0.69% | Added +14% |
| BIIB Biogen Inc. | 50,000 | $12.5M | 0.68% | New |
| PRME Prime Medicine, Inc. | 3,167,175 | $12.1M | 0.66% | Unchanged |
| ANL Adlai Nortye Group Ltd. | 1,250,000 | $11.3M | 0.62% | Unchanged |
| EWTX Edgewise Therapeutics, Inc. | 265,000 | $10.8M | 0.59% | New |
| ORIC ORIC Pharmaceuticals, Inc. | 1,250,000 | $9.8M | 0.54% | New |
| AGMB AgomAb Therapeutics NV | 1,550,000 | $8.5M | 0.46% | Unchanged |
| ABSI Absci Corporation | 973,260 | $7.8M | 0.43% | Unchanged |
| BRVE Braveheart Bio, Inc. | 400,000 | $7.8M | 0.43% | New |
| BNTX BioNTech SE | 85,000 | $7.0M | 0.38% | New |
| VCYT Veracyte, Inc. | 276,308 | $6.9M | 0.38% | Unchanged |
| RAPP Rapport Therapeutics, Inc. | 200,000 | $4.7M | 0.26% | New |
| NTLA Intellia Therapeutics, Inc. | 355,000 | $3.6M | 0.20% | Unchanged |
| IPSC Century Therapeutics, Inc. | 1,228,190 | $1.6M | <0.1% | Unchanged |
| CTNM Contineum Therapeutics, Inc. | 148,333 | $1.3M | <0.1% | Unchanged |
| PACB Pacific Biosciences of California, Inc. | 723,767 | $1.2M | <0.1% | Unchanged |
| EDIT Editas Medicine, Inc. | 445,000 | $772K | <0.1% | Unchanged |
| GLUE Monte Rosa Therapeutics, Inc. | 86,014 | $765K | <0.1% | Reduced −54% |
| KARD Kardigan, Inc. | 50,000 | $621K | <0.1% | Unchanged |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 282,312 | $529K | <0.1% | Unchanged |
| RXRX Recursion Pharmaceuticals, Inc. | 165,323 | $446K | <0.1% | Unchanged |
| DNA Ginkgo Bioworks Holdings, Inc. | 36,493 | $290K | <0.1% | Unchanged |
| TNYA Tenaya Therapeutics, Inc. | 361,969 | $109K | <0.1% | Unchanged |